2022
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.Peer-Reviewed Original Research
2020
Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patterns